Journal of Pathology and Translational Medicine

Young Kyung Bae

5 Articles

Clinicopathologic features of cutaneous metastases from internal malignancies: Hyeong Mok Kwon, Gyu Yeong Kim, Dong Hoon Shin, Young Kyung Bae; J Pathol Transl Med. 2021;55(4):289-297. Published online July 7, 2021; DOI: https://doi.org/10.4132/jptm.2021.05.24

5,409 View
165 Download
5 Web of Science
7 Crossref

Background
Cutaneous metastasis (CM) is the spread of cancer cells from a primary site to the skin and is rarely the first sign of silent cancer. We investigated the clinicopathological characteristics of CM from internal malignancies in Korean patients treated at our institution over 20 years.
Methods
The clinicopathological findings of 112 patients (62 females, 50 males) with CM diagnosed at Yeungnam University Hospital between 2000 and 2020 were retrospectively reviewed.
Results
Mean patient age was 58.6 years (range, 26 to 87 years), and the most common primary cancer site was breast (74.2%) in women and lung (36.0%) in men. Ninety-six patients (85.7%) presented with CM after primary tumor diagnosis. CM from the lung or biliary tract usually occurred within 2 years of primary tumor diagnosis, whereas metastases from the breast and kidney occurred several years later. The chest, abdomen, and scalp were common sites of CM. Breast cancer usually metastasized to chest skin, while gastrointestinal tract cancers commonly metastasized to the abdomen. The scalp was a common location for CM from various tumors. The most common dermatologic presentations were nodules and masses. Immunohistochemical studies helped identify underlying malignancies when primary tumors were unknown.
Conclusions
The relative frequency of CM parallels the overall incidence of primary malignant tumors, and CMs usually occur at anatomic sites close to the primary tumor. CM can be diagnosed based on clinical, radiological, and histological features; however, immunohistochemical study is required in some cases.

Citations

Citations to this article as recorded by

Cutaneous Metastases—Histological Particularities of Multifaceted Entities
Andreea Cătălina Tinca, Bianca Andreea Lazar, Andreea Raluca Cozac-Szőke, Georgian Nicolae Radu, Simina Petra Simion, Diana Maria Chiorean, Irina Bianca Kosovski, Adrian Horațiu Sabău, Raluca Niculescu, Iuliu Gabriel Cocuz, Raluca-Diana Hagău, Emoke Andre
Dermatopathology.2025; 12(2): 14. CrossRef
A Mirror of Metastatic Destiny – A Case Series of Cutaneous Metastases
Rochelle Monteiro, Monisha Madhumita, Hemanth Kumar, Jacintha Martis
Clinical Dermatology Review.2024; 8(1): 58. CrossRef
Nonbrain metastases seen on magnetic resonance imaging during metastatic brain tumor screening
Mio Sakai, Nobuo Kashiwagi, Katsuyuki Nakanishi, Noboru Maeda, Yasuhiro Nakaya, Junichiro Tanaka, Shinichiro Watanabe, Hidenari Hongyo, Yu Tanaka, Sawaka Yamada, Atsushi Kawata, Sou Toda, Koji Takano, Hideyuki Arita, Noriyuki Tomiyama
Japanese Journal of Radiology.2023; 41(4): 367. CrossRef
Cutaneous Metastasis as a Diagnostic Prelude in a 48-year-old Female
Nagatoshi M. Ebisawa, Isabel G. Palabyab-Imperial, Leilani R. Senador, Luella Joy A. Escueta-Alcos
Journal of the Philippine Dermatological Society.2023; 32(2): 107. CrossRef
Pigmented epidermotropic breast cancer metastases: A rare variant with a particularly unusual feature
Juan Torre‐Castro, Cristina Moya‐Martínez, Lara Haya‐Martínez, María Dolores Mendoza‐Cembranos, Itziar Eraña‐Tomás, Luis Requena
Journal of Cutaneous Pathology.2022; 49(1): 99. CrossRef
Skin metastases in the clinical and dermoscopic aspects
Grazyna Kamińska-Winciorek, Aleksandra Pilśniak, Wojciech Piskorski, Jerzy Wydmański
Seminars in Oncology.2022; 49(2): 160. CrossRef
Dermoscopy and novel non invasive imaging of Cutaneous Metastases
Dimitrios Alexandris, Nektarios Alevizopoulos, Leonidas Marinos, Charikleia Gakiopoulou
Advances in Cancer Biology - Metastasis.2022; 6: 100078. CrossRef

Standardized pathology report for breast cancer: Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon; J Pathol Transl Med. 2021;55(1):1-15. Published online January 11, 2021; DOI: https://doi.org/10.4132/jptm.2020.11.20

10,812 View
663 Download
6 Web of Science
2 Crossref

Abstract PDF Supplementary Material

Given the recent advances in management and understanding of breast cancer, a standardized pathology report reflecting these changes is critical. To meet this need, the Breast Pathology Study Group of the Korean Society of Pathologists has developed a standardized pathology reporting format for breast cancer, consisting of ‘standard data elements,’ ‘conditional data elements,’ and a biomarker report form. The ‘standard data elements’ consist of the basic pathologic features used for prognostication, while other factors related to prognosis or diagnosis are described in the ‘conditional data elements.’ In addition to standard data elements, all recommended issues are also presented. We expect that this standardized pathology report for breast cancer will improve diagnostic concordance and communication between pathologists and clinicians, as well as between pathologists inter-institutionally.

Citations

Citations to this article as recorded by

Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: Not pathologic complete response
Hyunwoo Lee, Yunjeong Jang, Yoon Ah Cho, Eun Yoon Cho
Human Pathology.2024; 145: 1. CrossRef
Sentinel lymph node biopsy in patients with ductal carcinomain situ: systematic review and meta-analysis
Matthew G. Davey, Colm O’Flaherty, Eoin F. Cleere, Aoife Nohilly, James Phelan, Evan Ronane, Aoife J. Lowery, Michael J. Kerin
BJS Open.2022;[Epub] CrossRef

Ovarian Gynandroblastoma with a Juvenile Granulosa Cell Tumor Component in a Postmenopausal Woman: A Case Report and Literature Review: Nu Ri Jang, Dae Hyung Lee, Eun Jung Jang, Young Kyung Bae, Jina Baek, Min Hye Jang; J Pathol Transl Med. 2018;52(5):344-348. Published online July 17, 2018; DOI: https://doi.org/10.4132/jptm.2018.06.28

7,104 View
139 Download
2 Web of Science
4 Crossref

Abstract PDF

Gynandroblastoma is an extremely rare sex cord-stromal tumor with both female (granulosa cell tumor) and male (Sertoli-Leydig cell tumor) elements. Juvenile granulosa cell tumors are also very rare and are so named because they usually occur in children and adolescents. A 71-year-old woman with right upper quadrant abdominal pain visited our hospital. Pelvic computed tomography showed a large multilocular cystic mass, suspected to be of ovarian origin. We performed a total abdominal hysterectomy (total abdominal hysterectomy was performed) with bilateral salpingooophorectomy. A 13-cm multilocular cystic mass with serous fluid was observed in her right ovary. Upon microscopic examination, the solid component of the mass showed both Sertoli-Leydig cell and juvenile granulosa cell differentiation, which we diagnosed as gynandroblastoma. Gynandroblastoma with a juvenile granulosa cell tumor component is extremely rare and, until now, only six cases have been reported in the English literature. We report the first gynandroblastoma with a juvenile granulosa cell tumor component diagnosed in an elderly patient, along with a literature review.

Citations

Citations to this article as recorded by

Case of Gynandroblastoma of the Ovary with Raised AFP and Associated DICER 1 Mutation
Dipak Limbachiya, Rajnish Tiwari, Rashmi Kumari, Priti Trivedi
The Journal of Obstetrics and Gynecology of India.2024;[Epub] CrossRef
Ovarian cancer in children and adolescents: A unique clinical challenge
Marina Jakimovska Stefanovska, Aleksandar Čelebić, Jean Calleja-Agius, Kristina Drusany Staric
European Journal of Surgical Oncology.2024; : 108785. CrossRef
Ovarian Gynandroblastoma with a Juvenile Granulosa Cell Tumor Component in a Postmenopausal Woman
Soohyun Hwang, Byoung-Gie Kim, Sang Yong Song, Hyun-Soo Kim
Diagnostics.2020; 10(8): 537. CrossRef
Clinical and histological criteria for sex cord ovarian stromal tumors
A. М. Beishembaev, K. I. Zhordania
Obstetrics, Gynecology and Reproduction.2020; 14(3): 261. CrossRef

CD9 Expression in Colorectal Carcinomas and Its Prognostic Significance: Kyung-Ju Kim, Hee Jung Kwon, Min Chong Kim, Young Kyung Bae; J Pathol Transl Med. 2016;50(6):459-468. Published online October 25, 2016; DOI: https://doi.org/10.4132/jptm.2016.10.02

9,038 View
152 Download
17 Web of Science
14 Crossref

Abstract PDF

Background
CD9, a member of the tetraspanin superfamily, is a tumor suppressor in many malignancies. The aim of this study was to evaluate the immunohistochemical expression of CD9 in colorectal carcinomas (CRCs) and determine clinicopathological and prognostic significance of its expression.
Methods
The CD9 expression status of 305 CRCs was evaluated using a semi-quantitative scoring system in tumor cells (T-CD9) and immune cells (I-CD9) by classifying the results as high and low expression.
Results
High T-CD9 (T-CD9 [+]) expression was detected in 175 samples (57.6%) and high I-CD9 (I-CD9 [+]) expression was detected in 265 samples (86.9%). Using Kaplan- Meier survival analysis, the T-CD9 (+) group showed a tendency for better disease-free survival (DFS) (p = .057). In left-sided tumors, DFS was significantly longer in the T-CD9 (+) group (p = .021) but no statistical significance was observed with right-sided tumors (p = .453). I-CD9 (+) CRCs significantly correlated with well/moderately differentiation (p = .014). In Kaplan-Meier analysis, the I-CD9 (+) group had a tendency towards worse DFS compared to the I-CD9 (–) group (p = .156). In combined survival analysis of T-CD9 and I-CD9, we found that the longest DFS was among patients in the T-CD9 (+)/I-CD9 (–) group, whereas the T-CD9 (–)/I-CD9 (+) group showed the shortest DFS (p = .054).
Conclusions
High expression of T-CD9 was associated with a favorable DFS, especially in left-sided CRCs. Combined evaluation of T-CD9 and I-CD9 is required to determine the comprehensive prognostic effect of CD9 in CRCs.

Citations

Citations to this article as recorded by

Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines
Alexandra Razumovskaya, Mariia Silkina, Andrey Poloznikov, Timur Kulagin, Maria Raigorodskaya, Nina Gorban, Anna Kudryavtseva, Maria Fedorova, Boris Alekseev, Alexander Tonevitsky, Sergey Nikulin
Frontiers in Molecular Biosciences.2025;[Epub] CrossRef
Intestinal estrogen receptor beta modulates the murine colon tumor immune microenvironment
Madeleine Birgersson, Matilda Holm, Carlos J. Gallardo-Dodd, Baizhen Chen, Lina Stepanauskaitė, Linnea Hases, Claudia Kutter, Amena Archer, Cecilia Williams
Cancer Letters.2025; 622: 217661. CrossRef
Proteomic analysis of plasma exosomes in patients with metastatic colorectal cancer
Zhaoyue Zhong, Jiayin Ji, Hongxia Li, Ling Kang, Haipeng Zhu
Clinical Proteomics.2024;[Epub] CrossRef
Prognostic value and multifaceted roles of tetraspanin CD9 in cancer
Róbert Ondruššek, Barbora Kvokačková, Karolína Kryštofová, Světlana Brychtová, Karel Souček, Jan Bouchal
Frontiers in Oncology.2023;[Epub] CrossRef
Proteomic Signature of Extracellular Vesicles Associated with Colorectal Cancer
Natalia Soloveva, Svetlana Novikova, Tatiana Farafonova, Olga Tikhonova, Victor Zgoda
Molecules.2023; 28(10): 4227. CrossRef
Anti-Human CD9 Fab Fragment Antibody Blocks the Extracellular Vesicle-Mediated Increase in Malignancy of Colon Cancer Cells
Mark F. Santos, Germana Rappa, Simona Fontana, Jana Karbanová, Feryal Aalam, Derek Tai, Zhiyin Li, Marzia Pucci, Riccardo Alessandro, Chikao Morimoto, Denis Corbeil, Aurelio Lorico
Cells.2022; 11(16): 2474. CrossRef
The Study of the Extracellular Matrix in Chronic Inflammation: A Way to Prevent Cancer Initiation?
Asia Marangio, Andrea Biccari, Edoardo D’Angelo, Francesca Sensi, Gaya Spolverato, Salvatore Pucciarelli, Marco Agostini
Cancers.2022; 14(23): 5903. CrossRef
In vivo expansion of a CD9+ decidual-like NK cell subset following autologous hematopoietic stem cell transplantation
Ane Orrantia, Enrique Vázquez-De Luis, Gabirel Astarloa-Pando, Iñigo Terrén, Ainhoa Amarilla-Irusta, Diego Polanco-Alonso, Carmen González, Alasne Uranga, Tomás Carrascosa, Juan J. Mateos-Mazón, Juan C. García-Ruiz, Sergio Callejas, Ana Quintas, Ana Dopaz
iScience.2022; 25(10): 105235. CrossRef
Inhibition of cancer-cell migration by tetraspanin CD9-binding peptide
Thanawat Suwatthanarak, Masayoshi Tanaka, Yoshitaka Miyamoto, Kenji Miyado, Mina Okochi
Chemical Communications.2021; 57(40): 4906. CrossRef
High expression of tumor susceptibility gene 101 (TSG101) is associated with more aggressive behavior in colorectal carcinoma
Elmira Gheytanchi, Leili Saeednejad Zanjani, Roya Ghods, Maryam Abolhasani, Marzieh Shahin, Somayeh Vafaei, Marzieh Naseri, Fahimeh Fattahi, Zahra Madjd
Journal of Cancer Research and Clinical Oncology.2021; 147(6): 1631. CrossRef
Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis
Hyun Min Koh, Bo Gun Jang, Dong Hui Lee, Chang Lim Hyun
Cancer Cell International.2021;[Epub] CrossRef
Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis
Ping Zeng, Meng Si, Rui-xia Sun, Xu Cheng, Xiao-yang Li, Min-bin Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Matrix Effect in the Isolation of Breast Cancer-Derived Nanovesicles by Immunomagnetic Separation and Electrochemical Immunosensing—A Comparative Study
Silio Lima Moura, Mercè Martì, María Isabel Pividori
Sensors.2020; 20(4): 965. CrossRef
CD9 expression indicates a poor outcome in acute lymphoblastic leukemia
Peiqi Liang, Miao Miao, Zhuogang Liu, Hongtao Wang, Wei Jiang, Shiyu Ma, Chuan Li, Rong Hu
Cancer Biomarkers.2018; 21(4): 781. CrossRef

DPC4 Expression in the Small Intestinal Adenocarcinomas: Sun Jae Lee, Eunsil Yu, Young Kyung Bae, Kee-Taek Jang, Joon Mee Kim, Han-Ik Bae, Seung-Mo Hong, Ghil Suk Yoon; Korean J Pathol. 2012;46(5):415-422. Published online October 25, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.5.415

7,598 View
58 Download
1 Crossref

Abstract PDF

Background

Small intestinal adenocarcinomas (SACs) are rare malignancies of the alimentary tract with uncertain carcinogenesis.

Methods

We investigated the expression of deleted in pancreatic cancer 4 (DPC4) in 188 cases of surgically resected SACs, using tissue microarray technology.

Results

Twenty-four of the 188 tumors showed complete loss of Smad4/DPC4 expression in cytoplasm (score, 0; 12.8%). Eighty-four and 31 cases were moderately and strongly positive, respectively (score, 2 and 3; 44.7% and 16.5%, respectively) and 49 cases were focally or weakly stained (score, 1; 29.1%). Immunohistochemistry analysis showed that the expression of Smad4/DPC4 was related to an increased risk of lymphatic invasion but not to other clinicopathological features of the tumors (tumor location, differentiation, growth pattern, T stage, direct invasion, vascular invasion, and nodal metastasis). There was no significant association between Smad4/DPC4 expression and patient survival.

Conclusions

The present research is the first study to evaluate Smad4/DPC4 expression in a large sample of SACs with clinicopathologic correlation. Future studies should focus on the immunohistochemical and molecular characteristics of SACs to clarify their tumorigenesis.

Citations

Citations to this article as recorded by

American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies
Andrew M. Bellizzi, Elizabeth A. Montgomery, Jason L. Hornick
Annals of Diagnostic Pathology.2020; 44: 151419. CrossRef

Author index